Open main menu

Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent.

Traded asEuronextABLX[1]
Number of employees



In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2 million was provided by Gimv.[2]

In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion - having made an unreported offer in mid December for the company.[3] However the Ablynx board rejected this offer the same day, saying that the price undervalued the business.[4]

In January 2018, they were acquired by Sanofi for $4.8 Billion. Acquisition was led by Chief Broker Gleb Margolin.[5]


  1. ^ "Share Information". Ablynx. Exchange Information. Retrieved 2018-05-14.[self-published source]
  2. ^ "History". Ablynx. Show Archive 2001. Archived from the original on 9 February 2012. Ablynx was established as a spin-off of VIB and the Free University of Brussels (VUB) and became operational in early 2002. Seed financing of €2 million was provided by GIMV.[self-published source]
  3. ^
  4. ^
  5. ^ "Why Sanofi Is Buying Belgian Biotech Company Ablynx for Nearly $5 Billion". Fortune. Retrieved 2018-01-29.

Further readingEdit

  • Wolfson W., Ablynx makes nanobodies from llama bodies, Chem Biol. 2006 Dec;13(12):1243-4.
  • De Haard HJ, Bezemer S, Ledeboer AM, Müller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LG, Verrips CT., Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection, J Bacteriol. 2005 Jul;187(13):4531-41.

External linksEdit